公证天业会计师事务所(特殊普通合伙) Gongzheng Tianye Certified Public Accountants, SGP 您可使用手机"扫一扫"或进入"注册会计师行业统一监管平台（http://acc.mcf.gov.cn）"进行查验 "进行查用手机"扫一扫"或进入"注册会计师行业统一监管平台（http://acc.mt.6gov.cn）"进行查验 目 录 | 1、专项核查报告 .. | | --- | | 2、营业收入扣除情况表。 | | 3、事务所营业执照复印件 | | 4、事务所执业证书复印件 …………………………………………………… | | 5、签字注册会计师资质证明复印件 | 关于江苏艾迪药业股份有限公司 2023 年 营业收入扣除情况的 专项核查报告 苏公 W[2024]E1102 号 公证天业会计师事务所(特殊普通合伙) Gongzheng Tianye Certified Public Accountants, SGP | 中国. 江苏. 元锡 | | --- | | 总机:86 (510) 68798988 | | 传真:86(510)68567788 | | 电子信箱:m ...

&T PARTNERS 目仁律师事务所 江 苏世纪同仁律师事务所 关于江苏艾迪药业股份有限公司 实际控制人增持公司股份的 法律意见书 苏 同 律 证 字 (2024) 第 [052]号 南 京 市 建 邺 区 贤 坤 路 江 岛 智 立 方 C 座 4 层 F4, Building C, Jiangdao Intelligent Cube, Xiankun Road, Jianye District, Nanjing 电 话 /Tel: +86 25-83304480 传真/Fax: +86 25-83329335 邮 编 /P.C.: 210019 江苏世纪同仁律师事务所 关于江苏艾迪药业股份有限公司 实际控制人增持公司股份的法律意见书 苏同律证字 2024 第[052]号 致:江苏艾迪药业股份有限公司 根据《中华人民共和国公司法》(以下简称"《公司法》")《中华人民共 和国证券法》(以下简称"《证券法》")《上市公司收购管理办法》(以下简 称"《收购管理办法》")等法律、法规、规章及规范性文件的有关规定,本所 接受江苏艾迪药业股份有限公司(以下简称"艾迪药业"或"公司")的委托, 现就艾迪药业实际控制人增 ...

华泰联合证券有限责任公司 关于江苏艾迪药业股份有限公司 一、募集资金基本情况 经中国证券监督管理委员会出具的《关于同意江苏艾迪药业股份有限公司首 次公开发行股票注册的批复》（证监许可〔2020〕1185 号），公司向社会公开发行 人民币普通股 6,000 万股，发行价为每股人民币 13.99 元，募集资金总额为人民 币 839,400,000.00 元，扣除承销费用和保荐费用合计含税金额 61,758,000.00 元， 实际募集资金到账 777,642,000.00 元。本次股票发行累计发生发行费用含税人民 币 79,833,781.03 元，包含可抵扣增值税进项税额 4,506,826.42 元，扣除不含税的 发行费用后募集资金净额为人民币 764,073,045.39 元。 部分募投项目延期的核查意见 华泰联合证券有限责任公司（以下简称"华泰联合证券"或"保荐机构"）作为 江苏艾迪药业股份有限公司（以下简称"艾迪药业"或"公司"）首次公开发行股票 并在科创板上市项目的保荐机构，根据《证券发行上市保荐业务管理办法》《上 海证券交易所科创板股票上市规则》《科创板上市公司持续监管办法（试行）》等 相关规定履行 ...

Financial Performance - The company reported no cash dividends, stock bonuses, or capital reserve transfers for the 2023 profit distribution plan[5]. - The company has not achieved profitability since its listing[4]. - The company's operating revenue for 2023 reached ¥411,363,846.09, representing a 68.44% increase compared to ¥244,219,269.82 in 2022[21]. - The net profit attributable to shareholders of the listed company was -¥76,069,538.24 in 2023, an improvement from -¥124,093,297.16 in 2022[21]. - The net cash flow from operating activities was -¥166,224,918.89 in 2023, compared to -¥92,554,664.86 in 2022[21]. - Basic earnings per share for 2023 was -0.18 yuan, a 40% decrease compared to -0.30 yuan in 2022[22]. - The net profit attributable to shareholders decreased by 38.70% year-on-year, primarily due to increased sales and management expenses totaling 32.13 million yuan[22]. - The net cash flow from operating activities decreased by 79.60% compared to the previous year, attributed to higher salary and tax expenses[23]. - The weighted average return on equity improved by 3.34 percentage points to -6.56% compared to -9.90% in 2022[22]. - The total assets increased by 5.50% to ¥1,746,565,370.29 at the end of 2023, up from ¥1,655,549,092.77 at the end of 2022[21]. - The net assets attributable to shareholders of the listed company decreased by 6.13% to ¥1,125,538,212.91 at the end of 2023, down from ¥1,198,982,510.34 at the end of 2022[21]. Corporate Governance and Compliance - A standard unqualified audit report was issued by the accounting firm Tianye[5]. - The board of directors and supervisory board members have confirmed the accuracy and completeness of the annual report[5]. - There are no non-operational fund occupations by controlling shareholders or related parties[7]. - The company has not violated decision-making procedures for external guarantees[7]. - The company has not disclosed any special arrangements for corporate governance[7]. - The company has not reported any instances where a majority of directors could not guarantee the authenticity of the annual report[7]. - The company is subject to forward-looking statement risks, and investors should be cautious[6]. - The company has detailed various risk factors in its operations, which investors should consider[4]. Research and Development - The company is focused on the development of new pharmaceutical products and technologies, particularly in the area of Active Pharmaceutical Ingredients (APIs)[13]. - The company has made significant investments in research and development to support its product pipeline and innovation strategies[13]. - The company has 18 ongoing research projects, including 8 Class 1 new drugs and 4 Class 2 new drugs, with two Class 1 innovative drugs for HIV already approved and in the commercialization stage[48]. - The company is developing generic drugs for Darunavir and Dolutegravir, with Darunavir entering the pre-BE study phase and Dolutegravir in the BE study phase[43]. - The company has established a modern production and procurement system, ensuring compliance with GMP requirements in its production activities[67]. - The company has developed several core technologies in the field of human-derived proteins, including resin adsorption processes and purification techniques, all of which are self-developed[100]. - The company is actively working on new product development, including human-derived coagulation regulatory proteins and epidermal growth factors, based on its human-derived protein platform[100]. - The company has submitted registration materials for raw materials of ACC007, which have been accepted, ensuring raw material supply[108]. - The company has established project management teams for both human-derived protein and small molecule drug research, focusing on various aspects of drug development[71]. Market Expansion and Strategy - The company plans to expand its market presence and explore potential mergers and acquisitions to enhance growth opportunities[13]. - The company is actively preparing for registration in overseas markets, including Nigeria, Namibia, Tanzania, and South Africa, to expand its international presence[40]. - The company is expanding its management team, having appointed a new CEO, Chief Medical Officer, and other key positions to enhance its commercialization and management capabilities[45]. - The company is focusing on cost reduction and efficiency improvement, enhancing product competitiveness through scientific incentive policies and technological innovations[46]. - The company aims to provide a comprehensive range of antiviral products to meet the urgent demand for HIV treatment upgrades in China[43]. - The company is committed to addressing the urgent needs of HIV treatment in China by continuously enriching its research and development pipeline[41]. - The company is expanding its coverage to 30 provinces, autonomous regions, and municipalities, benefiting a growing number of HIV patients[56]. - The company plans to adjust the expected completion date for certain investment projects to June 30, 2025, due to delays in clinical trial progress[61]. - The company is committed to developing a pipeline of anti-HIV drugs, including integrase inhibitors and long-acting treatments, to meet diverse clinical needs[197]. Product Development and Innovation - The company launched its second innovative drug, AINOMITIP, which is the first domestic oral single-tablet combination innovative drug in the HIV treatment field, marking a significant milestone in China's antiviral drug development[34]. - AINOMITIP was successfully included in the National Medical Insurance Directory in December 2023, enhancing its affordability and accessibility for patients[36]. - The total sales revenue of HIV new drugs reached approximately 7,357.88 million yuan in 2023, reflecting a year-on-year increase of 119.67%[39]. - The company is advancing its innovative drug pipeline, including the new indication for AINOMITIP and the development of long-acting HIV treatment drugs[42]. - The company has established an innovative marketing model combining self-operated and commissioned sales to enhance the commercialization of HIV drugs in the domestic market[38]. - The company is developing a new generation integrase inhibitor, ACC017, which has entered Phase I clinical trials[58]. - The company is also developing generic versions of HIV medications, including ADC201 and ADC202, with progress in stability studies and bioequivalence testing[59]. - The company aims to enhance its core competitiveness by expanding its pipeline of HIV drugs targeting different treatment cycles and income levels[200]. Financial Management - The company incurred interest expenses of approximately 7.85 million yuan due to new bank loans taken during the reporting period[22]. - The total amount of trading financial assets decreased by 135.89 million yuan, impacting the profit for the period by 749,408.73 yuan[30]. - The company’s financial expenses surged to RMB 10.46 million, a dramatic increase of 2,525.42% due to increased bank borrowings[137]. - The investment cash flow net amount was RMB 73.44 million, a significant improvement from the previous year's negative cash flow[137]. - The company’s financing activities generated a net cash flow of 190.78 million RMB, a slight decrease of 2.68% from the previous year[158]. - Cash and cash equivalents increased by 67.04% to 225,355,528.66, primarily due to increased bank loans and the redemption of financial products[161]. - Accounts receivable rose by 60.25% to 182,416,036.14, attributed to increased revenue scale during the reporting period[162]. - Inventory increased by 18.40% to 184,877,931.55, reflecting normal stocking based on business development needs[162]. Sales and Marketing - The company has signed a strategic cooperation agreement with Fidson Pharmaceuticals in Nigeria to promote overseas commercialization of its HIV products[57]. - The company is focused on strengthening its sales team for HIV products to expand market share and enhance patient coverage[199]. - The company is conducting clinical research on several new drugs, including ACC017 and ADC201, targeting HIV infections[176]. - The company’s revenue from HIV diagnostic devices and reagents has decreased by 43.77% compared to the previous year[174]. - The company’s gross margin for HIV new drugs has increased by 8.80 percentage points compared to the previous year, reflecting improved profitability[174]. - The company’s total sales expenses for the reporting period amounted to 10,441.67 million RMB, representing an increase of 38.31% compared to the previous period, primarily due to intensified promotion efforts for new drugs[190]. Industry Outlook - The pharmaceutical industry in China is expected to maintain stable growth, driven by rapid economic growth, healthcare reforms, and an aging population[194]. - The market for anti-HIV drugs in China is projected to exceed 11 billion RMB by 2027, with the insurance channel expected to dominate the market at 61.8%[195]. - The global HIV drug market was valued at $32.5 billion in 2017 and is projected to reach $47.9 billion by 2025, with a compound annual growth rate (CAGR) of 6.0% from 2021 to 2025[81]. - The domestic HIV drug market is transitioning from government-funded treatments to a combination of government-funded, insurance-covered, and out-of-pocket options, enhancing accessibility and meeting diverse patient needs[84].

江苏艾迪药业股份有限公司 募集资金存放与实际使用情况的 鉴证报告 苏公 W[2024]E1105 号 公证天业会计师事务所(特殊普通合伙) Gongzheng Tianye Certified Public Accountants, SGP 您可使用手机"扫一扫"或进入"注册会计师行业统一监管平台（http://ac.mof.gov.ca）"进行变 。 您可使用手机"扫一扫"或进入"注册会计师行业统一监管平台（http://ac.mof.gov.co）"进行变 目 录 公证天业会计师事务所(特殊普通合伙) Gongzheng Tianye Certified Public Accountants, SGP 江苏 天锡 之机:86 (510) 68798988 86 (510) 68567788 箱: mail(@gztycpa.cn Wuxi. Jiangsu. China Tel: 86 (510) 68798988 Fax: 86 (510) 68567788 E-mail: mail@gztycpa.cn 江苏艾迪药业股份有限公司 募集资金存放与使用情况鉴证报告 江苏艾迪药业股份有限公司全体股东: 我们 ...

证券代码：688488 证券简称：艾迪药业 公告编号：2024-010 江苏艾迪药业股份有限公司 第二届董事会第二十一次会议决议公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律责任。 一、董事会会议召开情况 江苏艾迪药业股份有限公司（以下简称"公司"）第二届董事会第二十一次 会议通知于 2024 年 4 月 5 日以书面或邮件方式送达全体董事，会议于 2024 年 4 月 15 日在公司会议室以现场与通讯相结合的方式召开。本次会议由董事长傅和 亮先生主持，应到董事 7 名，实到董事 7 名。本次会议的召集和召开程序符合 《中华人民共和国公司法》和《公司章程》等相关规定。 二、董事会会议审议情况 与会董事就如下议案进行了审议，并表决通过以下事项： （一）审议通过《关于公司<2023年度总经理工作报告>的议案》 公司董事会认为：2023年，公司总经理按照有关规定认真履行职责，紧密围 绕着公司发展战略，扎实推动研发、生产、销售、经营管理等各项工作，同意通 过此议案。 表决结果：同意票7票，占董事总数100%；反对票0票，占董事总数 ...

证券代码：688488 证券简称：艾迪药业 公告编号：2024-012 江苏艾迪药业股份有限公司 关于实际控制人增持股份计划实施完毕 暨增持结果的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律责任。 重要内容提示： 增持计划基本情况：江苏艾迪药业股份有限公司（以下简称"公司"）于 2023 年 10 月 31 日披露了《江苏艾迪药业股份有限公司关于实际控制人增持股 份计划的公告》（公告编号：2023-073），公司实际控制人之一、董事长傅和亮先 生拟自 2023 年 10 月 31 日起 6 个月内，通过上海证券交易所交易系统允许的方 式（包括但不限于集中竞价和大宗交易）增持公司股份，合计增持金额不低于人 民币 500 万元且不超过人民币 1,000 万元。本次增持计划不设置增持股份价格区 间。 增持计划实施结果：自 2023 年 10 月 31 日起至 2024 年 4 月 15 日，傅和 亮先生通过上海证券交易所交易系统以集中竞价方式累计增持公司股份 589,700 股，占公司总股本的 0.14%，合计增持金额为人民币 ...

江苏艾迪药业股份有限公司 2023 年度会计师事务所履职情况评估报告 江苏艾迪药业股份有限公司（以下简称"公司"）聘请公证天业会计师事务 所（特殊普通合伙）（以下简称"公证天业"）作为公司 2023 年度财务报告审计 机构及内部控制审计机构。根据财政部、国务院国有资产监督管理委员会、中国 证券监督管理委员会颁布的《国有企业、上市公司选聘会计师事务所管理办法》， 公司对公证天业 2023 年度审计过程中的履职情况进行评估。经评估，公司认为， 公证天业在资质等方面合规有效，履职能够保持独立性，勤勉尽责，公允表达意 见。具体情况如下： 一、2023 年度会计师事务所基本情况 （一）会计师事务所基本情况 1、基本信息 （1）会计师事务所名称：公证天业会计师事务所（特殊普通合伙） （2）成立日期：公证天业创立于 1982 年，是全国首批经批准具有从事证券、 期货相关业务资格及金融业务审计资格的会计师事务所之一。2013 年 9 月 18 日， 转制为特殊普通合伙企业。 （5）执行事务合伙人/首席合伙人：张彩斌 （6）截至 2023 年末，公证天业合伙人数量 58 人，注册会计师人数 334 人， 签署过证券服务业务审计 ...

江苏艾迪药业股份有限公司 2023 年度独立董事述职报告（戚啸艳） 作为江苏艾迪药业股份有限公司（以下简称"公司"）的独立董事，2023 年 我在任职期间严格按照《中华人民共和国公司法》《中华人民共和国证券法》《上 市公司治理准则》《上市公司独立董事管理办法》《上海证券交易所科创板股票上 市规则》等相关法律、法规，以及《公司章程》《独立董事工作制度》等规定， 勤勉、尽责、诚信、独立地履行独立董事的职责，积极参加公司股东大会、董事 会及各专门委员会，充分发挥专业特长，为公司的经营发展提出合理化建议，促 进公司健康持续发展，切实维护了公司以及全体股东特别是中小股东的合法权益。 现将 2023 年度履行职责的情况汇报如下： 一、独立董事的基本情况 （一）独立董事人员情况 公司第二届董事会于 2022 年 3 月完成换届选举，共有 9 名董事，其中独立 董事 4 名；报告期内对《公司章程》进行修订后，公司共有 7 名董事，其中独立 董事 3 名，分别为王广基先生、郭子建先生、戚啸艳女士，占董事会人数三分之 一以上，符合相关法律法规及公司制度的规定。 （二）本人任职董事会专门委员会的情况 本人在董事会审计委员会、提名委 ...

证券代码：688488 证券简称：艾迪药业 公告编号：2024-018 江苏艾迪药业股份有限公司 第二届监事会第二十次会议决议公告 本公司监事会及全体监事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律责任。 一、监事会会议召开情况 江苏艾迪药业股份有限公司（以下简称"公司"）第二届监事会第二十次会 议通知于 2024 年 4 月 5 日送达全体监事。会议于 2024 年 4 月 15 日在公司会议 室召开。本次会议由公司监事会主席俞恒先生召集并主持，应到监事 3 人，实到 监事 3 人。本次会议的召集和召开程序符合《中华人民共和国公司法》和《公司 章程》等相关规定，会议形成的决议合法、有效。 二、监事会会议审议情况 与会监事就如下议案进行了审议，并表决通过以下事项： 1、审议通过《关于公司<2023 年度监事会工作报告>的议案》 公司监事会认为：2023 年，公司监事会按照《中华人民共和国公司法》《上 市公司治理准则》《上海证券交易所科创板股票上市规则》等法律、法规及规范 性文件，并依照《公司章程》和《监事会议事规则》的规定，认真履行职责。本 年度公 ...